The association with PD-L1 expression and ICI efficacy is context- and treatment-line-dependent in metastatic NSCLC, with studies demonstrating a benefit with ICIs in PD-L1-negative patients in the first-line setting in combination with chemotherapy and in the later lines as monotherapy [33,34]. Here, CD274 is linked to non-small cell lung carcinoma.